Multaq FDA Approved Drugs
MULTAQ [Dronedarone HydrochlorideC31H44N2O5SClH]
RX
- eq 400mg base (oral tablet)
Sanofi Aventis UsJul 1, 2009
- Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af.
- Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a daily with morning and evening meals.
- Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals.
- Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals.
- Reduction of the risk of cardiovascular hospitalization.
- Reduction of the risk of hospitalization for atrial fibrillation.
- Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.